Who are strontium-89's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tc-99m Pentetate, Fludeoxyglucose F 18 (FDG), PET Scan with [18F] VAT, Sr-89, Dexamethasone plus Radium-223, Tc 99m filtered sulfur colloid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/strontium-89.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

strontium-89 — Competitive Intelligence Brief

strontium-89 (strontium-89) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical; bone-seeking radioisotope. Area: Oncology.

marketed Radiopharmaceutical; bone-seeking radioisotope Hydroxyapatite in bone matrix; osteoblast uptake Oncology Small molecule Live · refreshed every 30 min

Target snapshot

strontium-89 (strontium-89) — Alberta Health services. Strontium-89 is a radioactive beta-emitting isotope that localizes to areas of increased bone metabolism and delivers targeted radiation to bone lesions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
strontium-89 TARGET	strontium-89	Alberta Health services	marketed	Radiopharmaceutical; bone-seeking radioisotope	Hydroxyapatite in bone matrix; osteoblast uptake
Tc-99m Pentetate	Tc-99m Pentetate	NYU Langone Health	marketed	Radiopharmaceutical diagnostic agent
Fludeoxyglucose F 18 (FDG)	Fludeoxyglucose F 18 (FDG)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
PET Scan with [18F] VAT	PET Scan with [18F] VAT	Stony Brook University	marketed	PET imaging agent / Radiopharmaceutical	Vascular adhesion molecules (VAM)
Sr-89	Sr-89	Peking Union Medical College Hospital	marketed	Radiopharmaceutical; beta-emitting radioisotope	Bone hydroxyapatite (calcium analog); osteoblasts in areas of increased bone metabolism
Dexamethasone plus Radium-223	Dexamethasone plus Radium-223	University Health Network, Toronto	marketed	Combination therapy: corticosteroid plus alpha-emitting radiopharmaceutical	Radium-223 targets calcium-mimetic bone uptake; dexamethasone targets glucocorticoid receptor
Tc 99m filtered sulfur colloid	Tc 99m filtered sulfur colloid	Memorial Health University Medical Center	marketed	Radiopharmaceutical diagnostic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical; bone-seeking radioisotope class)

Alberta Health services · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). strontium-89 — Competitive Intelligence Brief. https://druglandscape.com/ci/strontium-89. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab